of Clinical Investigation, which examined the mechanism through which dasatinib mediates its toxic pulmonary (1) with high rates of complete cytogenetic response (12-month response rates of 66% for imatinib and 77% for dasatinib). Of note, dasatinib has been shown to be more than 300 times more potent than imatinib in inhibiting BCR-ABL kinase in vitro, in addition to being more potent than imatinib on c-Kit, platelet-derived growth factor receptor (PDGFR), and Src family kinases (1).
Pulmonary arterial hypertension (PAH) is a chronic, progressive, occlusive vasculopathy of the pulmonary arteries. The disease process is characterized by vasoconstriction, vascular remodeling, and inflammation within the pulmonary arterial tree (2) .
Pulmonary vasodilator therapy is currently available, although no curative therapy has been identified.
Since the introduction of dasatinib earlier this decade, more than 100 cases of dasatinib-induced PAH have been reported in Europe (3) . When imatinib was introduced, no such increase in pulmonary vasculopathy was identified, and indeed, imatinib was studied in a randomized controlled trial as add-on therapy in PAH, because of promising case reports in addition to basic and translational work (4) .
Recently, in the Journal of Clinical Investigation, Guignabert et al. (3) published an elegant study that examined the mechanism through which dasatinib has mediated its toxic pulmonary vascular effects.
Monocrotaline administration and chronic hypoxia are 2 well-characterized, well-established rodent models of pulmonary hypertension (5) . In this paper by Guignabert et al. (3) , the authors found that exposing rats with dasatinib, before the administration of monocrotaline or exposure to hypoxia, resulted in markedly higher pulmonary artery pressures and increased pulmonary vascular remodeling, compared with rats that were not pre-treated with From the Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah. Dr. Ryan has reported that he has no relationships relevant to the contents of this paper to disclose.
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Tyrosine Kinase Inhibition in PAH kinase with Src inhibitor-1 did not demonstrate any apoptotic effect, suggesting that the dasatinibinduced pulmonary endothelial cell apoptosis is independent of Src inhibition. The authors did find that dasatinib stimulated mitochondrial reactive oxygen species production in vitro, and this increase in oxidative stress contributed to pulmonary endothelial cell apoptosis.
TRANSLATIONAL PERSPECTIVE
The intersection between CML and PAH is, at first glance, a surprising one. However, upon closer review, No therapies have been developed to successfully regress that occlusive process (2) .
In the IMPRES trial (Imatinib in Pulmonary Arterial
Hypertension, a Randomized, Efficacy Study), patients with PAH were randomized in a 1:1 ratio to imatinib or placebo once daily. Imatinib improved exercise capacity, as measured by 6-min walk distance and hemodynamics in patients with advanced PAH, with a significant increase in cardiac output, but admittedly little effect on mean pulmonary artery pressure (4) . Thus, although pulmonary vascular resistance decreased, it was not clear whether there was regression of the pulmonary vasculopathy, despite imatinib being an antiproliferative agent.
Serious adverse events, most particularly subdural hematoma, were common, and in general, the drug was poorly tolerated, with frequent study drug discontinuations occurring in the study.
Thus, the conflicting nature of our experiences with these 2 BCR-ABL TKI offers valuable insight into the pathophysiology of PAH. On the one hand, we have an agent, imatinib, that successfully decreased pulmonary vascular resistance in vivo, albeit with significant adverse clinical effects. On the other hand, we have a more potent antiproliferative agent, dasatinib, which has been associated with increased pulmonary artery pressures and pulmonary vascular remodeling. We must take some time analyzing and reflecting on the overlap and differences between these 2 drugs, as presented by Guignabert et al. (3) in the Journal of Clinical Investigation. The future of PAH therapy relies on unlocking the secrets to the hyperproliferative pathways in PAH. The more we understand the phenomena seen by manipulating the tyrosine kinase pathway within the pulmonary vasculature, the closer we will get to developing successful antiproliferative medications of this disease.
